Hand Eczema Treatment Market- Analysis, Size, Forecast 2033

Hand Eczema (HE) Treatment Market Snapshot (2023 to 2033)

The global Hand Eczema (HE) Treatment Market is expected to garner a market value of US$ 53 Million in 2023 and is expected to accumulate a market value of US$ 114.42 Million by registering a CAGR of 8% in the forecast period 2023 to 2033. The market for Hand Eczema (HE) Treatment registered a CAGR of 4% in the historical period 2018 to 2022.

The Hand Eczema (HE) Treatment market is a segment of the healthcare industry that deals with the effective management of Hand Eczema (HE). The Hand Eczema (HE) Treatment market offers a range of products and services for its effective management and treatment such as phototherapy and other procedures. Treatment for hand eczema, a skin condition characterized by red, itchy, and dry skin on the hands, is expected to grow due to increasing awareness about skin care and an increasing incidence of hand eczema.

Report Attribute	Details
Expected Market Value (2023)	US$ 53 Million
Anticipated Forecast Value (2033)	US$ 114.42 Million
Projected Growth Rate (2023 to 2033)	8% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Hand Eczema (HE) Treatment Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider, Future Market Insights- the market for Hand Eczema (HE) Treatment reflected a value of 4% during the historical period, 2018 to 2022.

According to Studies, 31.6 million people (10.1%) in the U.S. have some form of eczema, and prevalence peaks during early childhood. The incidence of hand eczema is increasing globally, due to factors such as increased exposure to irritants, genetics, and underlying skin conditions. Furthermore, the growing focus on personal hygiene and skin care is increasing the demand for hand eczema treatment products and services.

In its new study, Future Market Insights (FMI) offers insights about key factors driving demand for Hand Eczema (HE) Treatment. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of Hand Eczema (HE) Treatments is fuelling the market growth. Thus, the market for Hand Eczema (HE) Treatment is expected to register a CAGR of 8% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Hand Eczema (HE) Treatment Market?

Growing demand for natural and organic products for the treatment of hand eczema to push the market growth

The global market for Hand Eczema (HE) Treatment is primarily driven by the increasing prevalence of the disease, the development of new and effective treatment options, advancements in treatment technologies, development of new diagnostic technologies and the availability of more effective treatments. In addition, increased awareness of Hand Eczema (HE), has led to a higher healthcare expenditure, especially on natural and organic products, globally contributing to the growth of the market.

Owing to the growing awareness of the potential side effects of chemical-based products, consumers are increasingly looking for treatments that are made from natural ingredients and are free from harmful chemicals. This increased desire for a more holistic approach to skin care has led to the development of a range of natural and organic hand eczema treatments, including topical creams, ointments, and lotions made from ingredients such as aloe vera, chamomile, and calendula.

Furthermore, the prevalence of Hand Eczema (HE) is high in low and middle-income countries, offering a significant market opportunity for companies to expand their product offerings. The prevalence of Hand Eczema (HE) has increased in recent years due to factors such as increased international travel, urbanization, and the aging of the population, which is expected to drive demand for Hand Eczema (HE) Treatments.

In September 2021, the FDA approved Opzelura, a cream containing the drug ruxolitinib, for the treatment of mild to moderate atopic dermatitis in patients aged 12 and above who either cannot use other topical treatments or have not seen enough improvement from them. Opzelura is the first JAK inhibitor, both oral and topical, to be approved for eczema. As it functions differently from other treatments for atopic dermatitis, it may provide relief to individuals who have not found success with other therapies, according to physicians.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Hand Eczema (HE) Treatment Market?

Expensive Cost of Treatment to restrict Market Growth

The market is projected to get significantly affected by the challenging factors such as limited availability and high cost of advanced Hand Eczema (HE) Treatment options. Expensive treatments and related costs such as hospitalization, intensive care, or specialized diagnostic tests, is expected to hinder the market growth. Furthermore, poor healthcare infrastructure, especially in developing countries, can limit access to Hand Eczema (HE) Treatment and the availability of diagnostic and therapeutic options.

Region-Wise Insights

How is the Hand Eczema (HE) Treatment Market Turning Out in the Asia Pacific Region?

Improvement in healthcare spending propelling growth of Hand Eczema (HE) Treatment in Asia Pacific

The Asia Pacific is expected to exhibit the significant growth rate over the forecast period, with a share of 20% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Hand Eczema (HE) Treatment Market in the region. Asia Pacific is an emerging market due to the increase in point of care approach to health & care. Increasing number of hospitals in India and China makes a promising market for the market worldwide.

What are the Factors Boosting the Market for Hand Eczema (HE) Treatment in North America?

Increasing Prevalence of Skin Conditions Shaping Landscape for Hand Eczema (HE) Treatment in North America

North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. According to the National Eczema Association, in 2019, around 31.6 million people in the United States had some form of eczema. The United States of America holds the highest share in the North American market, followed by Canada. Factors such as a large and aging population, increasing awareness about Hand Eczema (HE), high disposable income levels and the presence of a large patient population are expected to further drive market growth in the United States are leading to the growth of the market.

Category-Wise Insights

By End-users, Which Segment is Likely to Account for a Significant Share?

Hospitals to take the lead and drive market growth

According to the FMI analysis, Hospital pharmacy accounts for the largest market share. The requirement for several hospital stays and visits during the hand eczema treatment facilitates the growth of this segment. Majority of skin problems are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.

Startup Scenario

Key startups in the Hand Eczema (HE) Treatment market include

Canadian startup Derm-Biome Pharmaceuticals develops natural product pharmaceuticals to improve skin health. The startup derives pharmaceuticals from betulinic acid, obtained from birch barks. Among others, the lead derivative shows promise in the treatment of atopic dermatitis, psoriasis, acne, and neoplasticism skin disease.
Based in Italy, Omnidermal builds the medical device WoundViewer that monitors, documents, and classifies skin injuries in just two minutes. The device uses sensors and a camera that allows for its use in any lighting condition. As an example, the device’s artificial intelligence algorithm accurately recognizes and classifies ulcers. By speeding up the identification of skin ulcers, WoundViewer helps hospitals provide effective care and optimize patient management plans.
The team of United Kingdom startup Dermatica devises an evidence-based treatment and delivers it monthly. The startup’s web-based platform helps patients build a relationship with medical professionals and seek expert help when they need it. The startup also formulates treatments for acne, anti-aging, pigmentation, and melasma.

Market Competition

Key players in the market include pharmaceutical companies such as GlaxoSmithKline, Pfizer, Sanofi, Johnson & Johnson and Novartis along with the healthcare providers and technology companies among other global players.

In June 2022, FDA approved Dupixent (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis who are unable to control their condition with topical prescription therapies or when such treatments are not advisable. The approval was granted under Priority Review, which is reserved for treatments that show potential improvement in efficacy or safety in treating serious conditions. The approval is based on data from a Phase 3 trial comparing Dupixent (200 mg or 300 mg every four weeks based on body weight) with low-potency topical corticosteroids (TCS) or TCS alone (placebo).
In January 2022, Pfizer announced that the FDA has approved CIBINQO (abrocitinib), a once-daily oral Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate-to-severe atopic dermatitis in adults who are not adequately controlling their condition with other systemic treatments, including biologics, or when those treatments are not advisable.

Report Scope

Report Attribute	Details
Market Value in 2023	US$ 53 Million
Market Value in 2033	US$ 114.42 Million
Growth Rate	CAGR of 8% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Type End-User Region
Regions Covered	North America Latin America Europe Asia Pacific Middle East & Africa
Key Countries Profiled	USA Canada Brazil Argentina Germany United Kingdom France Spain Italy NorHand Eczema (HE)s BENELUX Australia & New Zealand China India Association of Southeast Asian Nations Gulf Cooperation Council South Africa
Key Companies Profiled	GlaxoSmithKline, Pfizer, Sanofi, Johnson & Johnson and Novartis
Customization	Available Upon Request

Key Segments Profiled in the Hand Eczema (HE) Treatment Industry Survey

Type:

Topical Corticosteroids
Topical Calcineurin Inhibitors
UV Therapy

End-User:

Retail Pharmacy
Hospital Pharmacy
Online Pharmacy

Region:

North America
Latin America
Europe
Asia Pacific
Middle East & Africa

Frequently Asked Questions

What is the Projected Size of the Hand Eczema Treatment Market by 2033?

The global market size to reach US$ 114.42 million by 2033.

Top Key Players in the Hand Eczema Treatment Market?

Pfizer, Sonafi and Johnson & Johnson are the top key players.

What is the Growth Potential of the Hand Eczema Treatment Market?

The global market is estimated to secure a CAGR 8% through 2033.

What Limits the Growth Potential of the Hand Eczema Market?

Expensive cost of treatments are likely to limit market growth.

Which End Use Category is Highly Preferred?

The hospital segment is highly preferred in the global market.

Table of Content

1. Executive Summary | Hand Eczema (HE) Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
5.3.1. Topical Corticosteroids
5.3.2. Topical Calcineurin Inhibitors
5.3.3. UV Therapy
5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033
6.3.1. Hospitals
6.3.2. Speciality Centers
6.3.3. Ambulatory Surgical Centers
6.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Type
8.2.3. By End Users
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Type
8.3.3. By End Users
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Type
9.2.3. By End Users
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type
9.3.3. By End Users
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. United kingdom
10.2.1.2. Spain
10.2.1.3. Germany
10.2.1.4. Italy
10.2.1.5. France
10.2.1.6. Rest of Europe
10.2.2. By Type
10.2.3. By End Users
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By End Users
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. India
11.2.1.2. China
11.2.1.3. Japan
11.2.1.4. Australia
11.2.1.5. Rest of Asia Pacific
11.2.2. By Type
11.2.3. By End Users
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By End Users
11.4. Key Takeaways
12. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. South Africa
12.2.1.2. GCC Countries
12.2.1.3. Rest of Middle East and Africa
12.2.2. By Type
12.2.3. By End Users
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By End Users
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. USA
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Type
13.1.2.2. By End Users
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Type
13.2.2.2. By End Users
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Type
13.3.2.2. By End Users
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Type
13.4.2.2. By End Users
13.5. United kingdom
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Type
13.5.2.2. By End Users
13.6. Spain
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Type
13.6.2.2. By End Users
13.7. Germany
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Type
13.7.2.2. By End Users
13.8. Italy
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Type
13.8.2.2. By End Users
13.9. France
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Type
13.9.2.2. By End Users
13.10. India
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Type
13.10.2.2. By End Users
13.11. China
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Type
13.11.2.2. By End Users
13.12. Japan
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Type
13.12.2.2. By End Users
13.13. Australia & New Zealand
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Type
13.13.2.2. By End Users
13.14. South Africa
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Type
13.14.2.2. By End Users
13.15. GCC Countries
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Type
13.15.2.2. By End Users
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Type
14.3.3. By End Users
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Sanofi
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Incyte Corporation
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Asana Biosciences
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Leo Pharma
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Regeneron Pharmaceuticals
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Meda AB
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. AstraZeneca
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Pfizer
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. GlaxoSmithKline plc
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Anacor Pharmaceuticals
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology

Hand Eczema (HE) Treatment Market

Hand Eczema (HE) Treatment Market by Type, End-Users & Region | Forecast 2023 to 2033